IS4553A - Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara - Google Patents

Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara

Info

Publication number
IS4553A
IS4553A IS4553A IS4553A IS4553A IS 4553 A IS4553 A IS 4553A IS 4553 A IS4553 A IS 4553A IS 4553 A IS4553 A IS 4553A IS 4553 A IS4553 A IS 4553A
Authority
IS
Iceland
Prior art keywords
monoamine oxidase
blockers
preparations containing
medicinal preparations
containing monoamine
Prior art date
Application number
IS4553A
Other languages
English (en)
Other versions
IS2789B (is
Inventor
Mary Brewer Francesca
Stewart Johnson Edward
Clarke Anthony
Original Assignee
R.P. Scherer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4553(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en
Application filed by R.P. Scherer Limited filed Critical R.P. Scherer Limited
Publication of IS4553A publication Critical patent/IS4553A/is
Publication of IS2789B publication Critical patent/IS2789B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
IS4553A 1995-03-02 1997-08-27 Lyfjablöndur sem innihalda mónóamínoxídasa B hemla IS2789B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9504235.4A GB9504235D0 (en) 1995-03-02 1995-03-02 Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en) 1995-03-02 1995-08-18 Pharmaceutical composition
PCT/GB1996/000484 WO1996026720A1 (en) 1995-03-02 1996-03-01 Pharmaceutical compositions comprising monoamine oxidase b inhibitors

Publications (2)

Publication Number Publication Date
IS4553A true IS4553A (is) 1997-08-27
IS2789B IS2789B (is) 2012-06-15

Family

ID=26306612

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4553A IS2789B (is) 1995-03-02 1997-08-27 Lyfjablöndur sem innihalda mónóamínoxídasa B hemla

Country Status (26)

Country Link
US (3) US20010021722A1 (is)
EP (1) EP0814789B2 (is)
JP (1) JP3273141B2 (is)
CN (1) CN1171586C (is)
AT (1) ATE241346T1 (is)
AU (1) AU702161B2 (is)
BG (1) BG63862B1 (is)
BR (1) BR9607057A (is)
CA (1) CA2214026C (is)
CZ (1) CZ297382B6 (is)
DE (1) DE69628415T3 (is)
DK (1) DK0814789T4 (is)
EE (1) EE04039B1 (is)
ES (1) ES2199283T5 (is)
GE (1) GEP20012374B (is)
HU (1) HU228852B1 (is)
IS (1) IS2789B (is)
MX (1) MX9706647A (is)
NO (1) NO316804B1 (is)
NZ (2) NZ302723A (is)
PL (1) PL183266B1 (is)
PT (1) PT814789E (is)
SI (1) SI0814789T2 (is)
SK (1) SK284383B6 (is)
TR (1) TR199700878T1 (is)
WO (1) WO1996026720A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
AU707646B2 (en) * 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
EP1171146B1 (en) * 1999-04-21 2004-06-23 Yuyu Inc. Pharmaceutical compositions containing selegiline and ginkgo biloba extract useful for treating dementia
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
WO2006057912A2 (en) * 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2007005845A1 (en) 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN1911211B (zh) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 雷沙吉兰口服固体制剂
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20070190187A1 (en) * 2006-09-07 2007-08-16 Kneller Bruce W Formulation for enhanced delivery of phenethylamine
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
JP2012527406A (ja) * 2009-05-20 2012-11-08 リングアル コンセグナ ピーティーワイ エルティーディー 口腔内および／または舌下治療用製剤
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
US10292947B2 (en) 2016-03-26 2019-05-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for N-propargylamine derivative

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
JP2660419B2 (ja) * 1988-04-02 1997-10-08 旭電化工業株式会社 安定化された合成樹脂組成物
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192550A (en) † 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
GB9017610D0 (en) * 1990-08-10 1990-09-26 Erba Carlo Spa Antiparkinson mao reversible inhibitor
EP0651997B1 (en) † 1991-12-24 1998-10-28 Yamanouchi Pharmaceutical Co. Ltd. Intrabuccally disintegrating preparation and production thereof
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
WO1993025197A1 (en) † 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU707646B2 (en) † 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
SI0814789T2 (sl) 2008-04-30
DE69628415D1 (de) 2003-07-03
US20040091525A1 (en) 2004-05-13
EP0814789B2 (en) 2008-01-09
DK0814789T3 (da) 2003-09-01
EP0814789B1 (en) 2003-05-28
ES2199283T3 (es) 2004-02-16
EE9700187A (et) 1998-02-16
SI0814789T1 (en) 2003-12-31
AU4884696A (en) 1996-09-18
GEP20012374B (en) 2001-03-25
HUP9801227A3 (en) 2000-02-28
WO1996026720A1 (en) 1996-09-06
BG101937A (en) 1998-07-31
EP0814789A1 (en) 1998-01-07
MX9706647A (es) 1998-06-30
JPH10506409A (ja) 1998-06-23
PL183266B1 (pl) 2002-06-28
NZ329471A (en) 1999-10-28
NO974010L (no) 1997-10-30
CZ270597A3 (cs) 1998-01-14
JP3273141B2 (ja) 2002-04-08
BR9607057A (pt) 1998-06-09
CN1178461A (zh) 1998-04-08
PL322046A1 (en) 1998-01-05
NZ302723A (en) 1998-04-27
US20080187573A1 (en) 2008-08-07
PT814789E (pt) 2003-09-30
HUP9801227A2 (hu) 1999-06-28
BG63862B1 (bg) 2003-04-30
HU228852B1 (en) 2013-06-28
CN1171586C (zh) 2004-10-20
CA2214026A1 (en) 1996-09-06
DE69628415T2 (de) 2004-03-11
SK284383B6 (sk) 2005-02-04
EE04039B1 (et) 2003-06-16
ES2199283T5 (es) 2008-05-16
ATE241346T1 (de) 2003-06-15
SK115897A3 (en) 1998-03-04
TR199700878T1 (xx) 1998-01-21
DE69628415T3 (de) 2008-06-26
NO974010D0 (no) 1997-09-01
CZ297382B6 (cs) 2006-11-15
CA2214026C (en) 2007-10-16
AU702161B2 (en) 1999-02-18
IS2789B (is) 2012-06-15
US20010021722A1 (en) 2001-09-13
DK0814789T4 (da) 2008-05-19
NO316804B1 (no) 2004-05-18

Similar Documents

Publication Publication Date Title
IS4553A (is) Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
ATE153853T1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
ATE525061T1 (de) Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
TR199800894T2 (xx) Biyo-yap��kan kat� dozaj formlar�.
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
NZ331953A (en) Benzopyran derivatives having leukotriene-antagonistic action
BR0014440A (pt) Formulações de liberação controlada oral
NO973401L (no) Kortikosteroidinneholdende sammensetninger og fremstilling derav
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
MD1218F1 (en) Antimutagenic agent
GT199400048A (es) Composicion farmaceutica y proceso para su preparacion
MD940244A (ro) Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor